Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
genetic diseases
Biotech
Otsuka pays Ionis $65M for European rights to rare disease drug
Otsuka is paying $65M upfront for European licensing rights to Ionis' donidalorsen, a treatment being developed for hereditary angioedema.
Gabrielle Masson
Dec 19, 2023 10:18am
Reneo pulls plug on rare disease asset, sinking stock 87%
Dec 14, 2023 10:16am
FDA launches new genetic metabolic disease advisory committee
Dec 12, 2023 12:35pm
Flagship's Alltrna collects $109M to Stop Codon Disease
Aug 9, 2023 6:00am
Pharnext ditches Alzheimer's plans to save cash
Feb 14, 2023 11:01am
Hormone that may improve cognition in Down syndrome identified
Sep 2, 2022 1:53pm